FDA: Just says NO — to ineffective drugs with side effects

FDA panel recommends against 1st drug for chronic fatigue syndrome December 21, 2012 by Steven Reinberg, Healthday Reporter in Medications

Excerpt 1: “…is a new type of drug called a nucleic acid compound, which uses specially made RNA to target a variety of diseases. Hemispherx believes the drug has the potential to fight HIV, kidney cancer and melanoma in addition to chronic fatigue syndrome. The drug is said to work by modulating the immune and antiviral functions in diseased cells.”

Excerpt 2: “Some experts think chronic fatigue syndrome is caused by a virus; others believe it is linked to a bacteria. It can begin after an illness from which a patient doesn’t quite recover, or the symptoms can appear almost overnight…”

My comment: I think I predicted, in part, this recommendation against the drug.
“Medical practitioners from ASAM and neuroscientists are more likely than psychologists to be aware that effective FDA-approved therapeutic intervention frequently involves pharmaceuticals that alter feedback on the GnRH neuronal system (Grumbach & Styne, 1992), which is the central neuronal system that is essential to species survival in all vertebrates (Kotitschke, Sadie-Van Gijsen, Avenant, Fernandes, & Hapgood, 2009) via its integral involvement in the acquisition of food and in sexual reproduction. ASAM seems to think that clinical psychologists should become more aware of currently accepted neuroscientific facts, which may be important to their understanding of… things that are not currently understood about the development of behavior.” – Kohl (2012).

A systems biology approach to chronic fatigue that incorporates neuroscientifically established fact is obviously required. For example, see GLYX-13, an NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects

About James V. Kohl 1307 Articles
James Vaughn Kohl was the first to accurately conceptualize human pheromones, and began presenting his findings to the scientific community in 1992. He continues to present to, and publish for, diverse scientific and lay audiences, while constantly monitoring the scientific presses for new information that is relevant to the development of his initial and ongoing conceptualization of human pheromones. Recently, Kohl integrated scientific evidence that pinpoints the evolved neurophysiological mechanism that links olfactory/pheromonal input to genes in hormone-secreting cells of tissue in a specific area of the brain that is primarily involved in the sensory integration of olfactory and visual input, and in the development of human sexual preferences. His award-winning 2007 article/book chapter on multisensory integration: The Mind’s Eyes: Human pheromones, neuroscience, and male sexual preferences followed an award winning 2001 publication: Human pheromones: integrating neuroendocrinology and ethology, which was coauthored by disinguished researchers from Vienna. Rarely do researchers win awards in multiple disciplines, but Kohl’s 2001 award was for neuroscience, and his 2007 “Reiss Theory” award was for social science. Kohl has worked as a medical laboratory scientist since 1974, and he has devoted more than twenty-five years to researching the relationship between the sense of smell and the development of human sexual preferences. Unlike many researchers who work with non-human subjects, medical laboratory scientists use the latest technology from many scientific disciplines to perform a variety of specialized diagnostic medical testing on people. James V. Kohl is certified with: * American Society for Clinical Pathology * American Medical Technologists James V. Kohl is a member of: * Society for Neuroscience * Society for Behavioral Neuroendocrinology * Association for Chemoreception Sciences * Society for the Scientific Study of Sexuality * International Society for Human Ethology * American Society for Clinical Laboratory Science * Mensa, the international high IQ society